Interestingly, the results of Merry and collaborators[50] (but not those of Gámez-Pozo et al.[47]) are concordant with the study above[64], where the authors observed that PRKACA expression was increased in breast cancer samples of HER2-positive trastuzumab-resistant breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.